Analysis of shape change in human pulmonary arterial smooth muscle cells by time lapse tomographic microscopy (~3 h per movie)


From JPET #239665

The selexipag active metabolite ACT-333679 displays strong anti-contractile and anti-remodeling effects, but low β-arrestin recruitment and desensitization potential

John Gatfield* , Katalin Menyhart, Daniel Wanner, Carmela Gnerre, Lucile Monnier, Keith Morrison, Patrick Hess, Marc Iglarz, Martine Clozel and Oliver Nayler

Actelion Pharmaceuticals Ltd, Allschwil, Switzerland

Supplemental movies to Figure 3.
Effect of the IP receptor agonist ACT-333679 on cellular shape change in human pulmonary arterial smooth muscle cells as determined by time lapse tomographic microscopy.
Cells were first (1.) treated either with ET-1 (100 nM) to induce cell contraction or with vehicle.
After 70-90 min cells were then treated (2.) either with ACT-333679 (1 μM) to induce relaxation or with vehicle.
Tomographic images were taken at regular intervals along the whole experimental period (˜180 min) and then converted to a smooth motion movie. Bar: 20 μm.



Experiments: Katalin Menyhart & John Gatfield
Image processing: Manuel Stritt




1. addition: ET-1
2. addition: selexipag active metabolite ACT-333679








1. addition: ET-1
2. addition: selexipag active metabolite ACT-333679








1. addition: ET-1
2. addition: selexipag active metabolite ACT-333679








1. addition: ET-1
2. addition: vehicle








1. addition: vehicle
2. addition: vehicle







Copyright © 2016 Actelion Pharmaceuticals Ltd